COMMUNIQUÉS West-GlobeNewswire

Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors

03/01/2019 - 14:30

- Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors – - Gregory J. Divis, current Avadel Chief Operating Officer, named Interim Chief Executive Officer – - Geoffrey M. [...]

Cellectar Biosciences to Present at the Biotech Showcase

03/01/2019 - 14:30

FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted [...]

ISS and Glass Lewis Recommend MPX Securityholders Vote in Favour of the Arrangement and MPX Shareholders Vote in Favour of the MPX Continuance and the MPX International Stock Option Plan

03/01/2019 - 14:30

TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (CSE: MPX) (OTC:MPXEF) (the “Company” or “MPX”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis and Co [...]

Wildflower Opens First New York CBD Retail Store

03/01/2019 - 14:30

VANCOUVER, British Columbia, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wildflower Brands Inc. (CSE: SUN) (the “Company”) is excited to announce the opening of its first Wildflower by Bridges General store in Lower Manhattan at [...]

Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome

03/01/2019 - 14:30

Meeting included representatives from NIH and BARDA HAIFA, Israel, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel [...]

Cabaletta Bio to Present at the 37th Annual J.P. Morgan Healthcare Conference

03/01/2019 - 14:30

RADNOR, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that [...]

Ultragenyx to Present at J.P. Morgan Healthcare Conference

03/01/2019 - 14:30

NOVATO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases [...]

Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck

03/01/2019 - 14:30

BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that [...]

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

03/01/2019 - 14:28

ENGLEWOOD, Colo., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has completed enrollment in its LIBERATE- [...]

Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer

03/01/2019 - 14:20

Seasoned healthcare professional with over 20 years of strategic finance, capital markets and transactional/business-related expertise BEDMINSTER, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc [...]

United Soybean Board Awards Grant to Amfora to Increase the Protein Content of U.S. Soy

03/01/2019 - 14:15

Group’s focus on protein reflects effort to maintain U.S. soy farmers’ global market share SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amfora, a biotechnology company that is applying gene editing to sustainably [...]

Obalon Announces Promotion of Amy VandenBerg to Chief Clinical & Regulatory Affairs Officer

03/01/2019 - 14:15

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric [...]

Allscripts to present at the J.P. Morgan 2019 Healthcare Conference

03/01/2019 - 14:01

CHICAGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) today announced that certain members of its management team will present at the J.P. Morgan 2019 Healthcare Conference in San Francisco, CA on Monday [...]

EDAP TMS SA : John Wayne Cancer Institute First US Medical Center to Acquire EDAP's Breakthrough Focal One® Technology for Prostate Tissue Ablation

03/01/2019 - 14:00

Focal One System Enhances Precision Tissue Ablation, Reduces Side Effects for Prostate Cancer Patients LYON, France -- January 3, 2019 - EDAP TMS SA (Nasdaq: EDAP) today announced that the John Wayne Cancer Institute ( [...]

Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference

03/01/2019 - 14:00

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth [...]

Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference

03/01/2019 - 14:00

NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial

03/01/2019 - 14:00

CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical [...]

Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer

03/01/2019 - 14:00

Phase 1 Data Expected the First Half of 2019 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for SM08502 [...]

Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference

03/01/2019 - 14:00

RP1: U.S. Enrollment Opened for Phase 1/2 Clinical Trial in Combination with Nivolumab in Patients with Solid Tumors RP1: Randomized Controlled Phase 2 Clinical Trial Alone and in Combination with Cemiplimab On Track to [...]